Postop Pain Management in Pituitary Tumour Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution: 2mL injection bilateral (4mL total) of 0.5% bupivacaine with 1:200,000 epinephrine solution, 20G needle, sterile, sphenopalatine ganglion; nerve block

Placebo: 2mL injection bilateral (4mL total) 0.9% saline solution, 20G needle, sterile, sphenopalatine ganglion; nerve block

Sham Comparator: Participants receive no additional study injections

Study summary

To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.

Eligibility

Primary outcome measure(s)

• Post-operative pain score — through study completion, approximately 1 year
  Pain score, measured by visual analog scale (scale of 0-10) at 6, 12 and 24 hours post-op

Trial sites (1)

More Hamilton Health Sciences Corporation trials in Canada

Other trials for the same condition